• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对中国流行期间各年龄段社区获得性肺炎患者肺炎支原体的分子特征分析和研究。

Molecular characterization and analysis of Mycoplasma pneumoniae among patients of all ages with community-acquired pneumonia during an epidemic in China.

机构信息

Department of Clinical Laboratory, The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China; Department of Infectious Diseases and Clinical Microbiology, Beijing Chao-Yang Hospital, Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, China.

Department of Clinical Trial, The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China.

出版信息

Int J Infect Dis. 2019 Jun;83:26-31. doi: 10.1016/j.ijid.2019.03.028. Epub 2019 Mar 26.

DOI:10.1016/j.ijid.2019.03.028
PMID:30926541
Abstract

BACKGROUND

Analysis of the molecular characteristics of isolates is very important for clinical and epidemiological study of community-acquired pneumonia (CAP) caused by Mycoplasma pneumoniae.

METHODS

Between 2010 and 2012, an epidemic period, M. pneumoniae was isolated from oropharyngeal swabs of consecutive CAP patients. Minimum inhibitory concentrations of macrolides, 23S rRNA gene sequencing, P1 gene and multilocus variable-number tandem-repeat analysis (MLVA) genotyping was conducted.

RESULTS

88.3% (181/205) of the isolates were macrolide-resistant M. pneumoniae (MRMP) and all harbored an A2063 G mutation. The strains were clustered into 7 MLVA types, and P1 type 1 and type 2 lineages were co-circulated (86.3% and 13.7%). Compared with adults, no specific MLVA type contributed to higher M. pneumoniae infection in children (p =  0.14). Similar macrolide profile and genotypes of M. pneumoniae was found between outpatients and inpatients. Significant differences in proportion of P1 types and two main MLVA types 4/5/7/2 and 3/5/6/2 were observed between MRMP and macrolide-sensitive M. pneumoniae (MSMP) (p <  0.001).

CONCLUSIONS

This study demonstrates a comprehensive profile of M. pneumoniae molecular characterization among CAP patients of all age, and provides more evidences on a correlation between MLVA type 4/5/7/2 and macrolide resistance in the setting of high incidence of MRMP.

摘要

背景

分析分离株的分子特征对于研究肺炎支原体(MP)引起的社区获得性肺炎(CAP)的临床和流行病学非常重要。

方法

在 2010 年至 2012 年的流行期间,连续从 CAP 患者的咽拭子中分离出 MP。对大环内酯类药物的最小抑菌浓度、23S rRNA 基因测序、P1 基因和多位点可变数串联重复分析(MLVA)基因分型进行分析。

结果

88.3%(181/205)的分离株为大环内酯耐药肺炎支原体(MRMP),均携带 A2063G 突变。菌株分为 7 种 MLVA 型,P1 型 1 和 2 谱系同时流行(86.3%和 13.7%)。与成人相比,儿童中特定的 MLVA 型并没有导致更高的 MP 感染(p=0.14)。门诊和住院患者的 MP 大环内酯谱和基因型相似。MRMP 和大环内酯敏感 MP(MSMP)之间 P1 型和两种主要 MLVA 型 4/5/7/2 和 3/5/6/2 的比例存在显著差异(p<0.001)。

结论

本研究全面描述了 CAP 患者中 MP 的分子特征,为高发生率的 MRMP 中 MLVA 型 4/5/7/2 与大环内酯耐药之间的相关性提供了更多证据。

相似文献

1
Molecular characterization and analysis of Mycoplasma pneumoniae among patients of all ages with community-acquired pneumonia during an epidemic in China.对中国流行期间各年龄段社区获得性肺炎患者肺炎支原体的分子特征分析和研究。
Int J Infect Dis. 2019 Jun;83:26-31. doi: 10.1016/j.ijid.2019.03.028. Epub 2019 Mar 26.
2
Emergence of Macrolide-Resistant Mycoplasma pneumoniae in Hong Kong Is Linked to Increasing Macrolide Resistance in Multilocus Variable-Number Tandem-Repeat Analysis Type 4-5-7-2.香港大环内酯类耐药肺炎支原体的出现与多位点可变数目串联重复序列分析4-5-7-2型中不断增加的大环内酯类耐药性有关。
J Clin Microbiol. 2015 Nov;53(11):3560-4. doi: 10.1128/JCM.01983-15. Epub 2015 Sep 2.
3
Genetic diversity and macrolide resistance of Mycoplasma pneumoniae isolates from two consecutive epidemics in Slovenia.斯洛文尼亚连续两次支原体肺炎流行株的遗传多样性与大环内酯类耐药性。
Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):99-107. doi: 10.1007/s10096-017-3106-5. Epub 2017 Sep 26.
4
Prevalence and Clinical Features of Community-Acquired Pneumonia Caused by Macrolide-Resistant Isolated from Adults in Jeju Island.济州岛成人分离的大环内酯类耐药的社区获得性肺炎的流行率和临床特征。
Microb Drug Resist. 2019 May;25(4):577-581. doi: 10.1089/mdr.2018.0295. Epub 2018 Nov 28.
5
First Detection and Characterization of Macrolide-Resistant from People with Community-Acquired Pneumonia in Iran.伊朗社区获得性肺炎患者中大环内酯类耐药 的首次检测和特征描述。
Microb Drug Resist. 2020 Mar;26(3):245-250. doi: 10.1089/mdr.2019.0223. Epub 2019 Sep 23.
6
[Survey of macrolide resistance in Mycoplasma pneumoniae in adult patients with community-acquired pneumonia in Beijing, China].[中国北京成年社区获得性肺炎患者肺炎支原体大环内酯类耐药性调查]
Zhonghua Jie He He Hu Xi Za Zhi. 2013 Dec;36(12):954-8.
7
The clinical significance of macrolide resistance in pediatric infection during COVID-19 pandemic.儿童感染大环内酯类耐药在 COVID-19 大流行期间的临床意义。
Front Cell Infect Microbiol. 2023 May 12;13:1181402. doi: 10.3389/fcimb.2023.1181402. eCollection 2023.
8
Prevalence, genotyping and macrolide resistance of Mycoplasma pneumoniae among isolates of patients with respiratory tract infections, Central Slovenia, 2006 to 2014.2006 年至 2014 年斯洛文尼亚中部分离的呼吸道感染患者肺炎支原体的流行率、基因分型和大环内酯类耐药性。
Euro Surveill. 2015;20(37). doi: 10.2807/1560-7917.ES.2015.20.37.30018.
9
Molecular Typing of Strains in Sweden from 1996 to 2017 and the Emergence of a New P1 Cytadhesin Gene, Variant 2e.1996 年至 2017 年瑞典分离株的分子分型及新型 P1 细胞黏附素基因变体 2e 的出现。
J Clin Microbiol. 2019 May 24;57(6). doi: 10.1128/JCM.00049-19. Print 2019 Jun.
10
Epidemiology and Molecular Characteristics of Mycoplasma pneumoniae During an Outbreak of M. pneumoniae-associated Stevens-Johnson Syndrome.肺炎支原体相关史蒂文斯-约翰逊综合征暴发期间肺炎支原体的流行病学及分子特征
Pediatr Infect Dis J. 2017 Jun;36(6):564-571. doi: 10.1097/INF.0000000000001476.

引用本文的文献

1
Clinical features associated with macrolides resistance of Mycoplasma pneumoniae pneumonia in children: a single-center analysis.儿童肺炎支原体肺炎大环内酯类耐药相关临床特征:单中心分析
BMC Infect Dis. 2025 Jul 1;25(1):854. doi: 10.1186/s12879-025-11234-5.
2
Antibiotic resistance and viral co-infection in children diagnosed with pneumonia caused by Mycoplasma pneumoniae admitted to Russian hospitals during October 2023-February 2024.2023年10月至2024年2月期间,俄罗斯医院收治的肺炎支原体肺炎患儿的抗生素耐药性和病毒合并感染情况。
BMC Infect Dis. 2025 Mar 15;25(1):363. doi: 10.1186/s12879-025-10712-0.
3
Comparative observation between Roxithromycin and Azithromycin sequential therapy in the treatment of Mycoplasma pneumoniae Pneumonia in Children.
罗红霉素与阿奇霉素序贯疗法治疗儿童支原体肺炎的对比观察
Pak J Med Sci. 2024 Oct;40(9):2124-2129. doi: 10.12669/pjms.40.9.8942.
4
The relationship between IFN-γ, IL-10, IL-6 cytokines, and severity of the condition with serum zinc and Fe in children infected with .γ干扰素、白细胞介素-10、白细胞介素-6细胞因子与感染……的儿童血清锌和铁水平及病情严重程度之间的关系
Open Med (Wars). 2024 Sep 6;19(1):20240987. doi: 10.1515/med-2024-0987. eCollection 2024.
5
Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.儿童大环内酯类耐药肺炎支原体肺炎诊断与治疗专家共识。
World J Pediatr. 2024 Sep;20(9):901-914. doi: 10.1007/s12519-024-00831-0. Epub 2024 Aug 14.
6
A preliminary prediction model of pediatric Mycoplasma pneumoniae pneumonia based on routine blood parameters by using machine learning method.基于机器学习方法的基于常规血液参数的小儿肺炎支原体肺炎初步预测模型。
BMC Infect Dis. 2024 Jul 18;24(1):707. doi: 10.1186/s12879-024-09613-5.
7
Observational retrospective clinical study on clinical features of macrolide-resistant Mycoplasma pneumoniae pneumonia in Chinese pediatric cases.观察性回顾性临床研究:中国儿科病例中大环内酯类耐药肺炎支原体肺炎的临床特征。
Sci Rep. 2024 Mar 7;14(1):5632. doi: 10.1038/s41598-024-55311-2.
8
Severe problem of macrolides resistance to common pathogens in China.中国常见病原体对大环内酯类药物的耐药性严重。
Front Cell Infect Microbiol. 2023 Aug 10;13:1181633. doi: 10.3389/fcimb.2023.1181633. eCollection 2023.
9
Application value of antibody titres and RNA detection in the early prediction of Mycoplasma pneumoniae pneumonia in children: a retrospective study.抗体滴度和 RNA 检测在儿童肺炎支原体肺炎早期预测中的应用价值:一项回顾性研究。
BMC Infect Dis. 2023 Apr 7;23(1):220. doi: 10.1186/s12879-023-08161-8.
10
Construction of a Nomogram for Identifying Refractory Pneumonia Among Macrolide-Unresponsive Pneumonia in Children.构建用于识别儿童大环内酯类无反应性肺炎中难治性肺炎的列线图
J Inflamm Res. 2022 Nov 30;15:6495-6504. doi: 10.2147/JIR.S387809. eCollection 2022.